|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | |  | | | | |  |  |  |  | | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  | | --- | | [Community Pharmacy England logo](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=86bfb6b135&e=d19e9fd41c) |  |  | | --- | | **Newsletter**  17th March 2025 | | | | | |  |  | | --- | --- | | |  | | --- | | The voice of community pharmacy (banner) | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **This newsletter - sent on Mondays, Wednesdays and Fridays - contains important information and resources to support community pharmacies across England.** | | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **In this update: Patient stories wanted; CPCF negotiations; Pharmacy IT group summary; OPD resources available; Discontinuation of Promixin®.** | | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  | | --- | --- | | |  | | --- | | [A blue and orange logo  AI-generated content may be incorrect.](mailto:comms.team@cpe.org.uk?subject=Patient%20case%20study) | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **In case you missed it:** We are still keen to find patients willing to speak publicly about their pharmacy-related experiences, and we need your help. We are particularly interested in two types of patient case studies:   * Patients willing to share their experiences of **medicine shortages**. * Patients who have been benefiting from the **Pharmacy First Service**.   We are keen to find case studies to help MPs and national media better understand the value of pharmacies to patients and the public.  If you can support us in identifying patients, please get in touch via [comms.team@cpe.org.uk](mailto:comms.team@cpe.org.uk?subject=Patient%20case%20study) | | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **CPCF Negotiations** | | |  |  |  | | --- | --- | | |  | | --- | | A white text on a green background  AI-generated content may be incorrect. | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **Pharmacy IT workstreams update published**  Community Pharmacy England has published a summary of the March 2025 Community Pharmacy IT Group (CP ITG) meeting, covering key topics such as EPS expansion, cybersecurity, NHS digital services, and the use of AI in patient care.  Pharmacy teams are encouraged to provide feedback, participate in pilot programs, and contribute to ongoing IT improvements. A [primary care cyber security survey](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=394fdd946d&e=d19e9fd41c) is also open until 6th April 2025.  [Learn more and get involved](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=29d940dd2c&e=d19e9fd41c) | | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  | | --- | --- | | |  | | --- | | [A close-up of a logo  AI-generated content may be incorrect.](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=26605ce37d&e=d19e9fd41c) | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | Original Pack Dispensing (OPD) with +/-10% flexibility was introduced for NHS prescriptions in January 2025. To support pharmacy teams with these changes, our in-house experts have developed a range of resources for guidance and practical support on implementing OPD in your pharmacy.  To access the following, please click the hyperlinks Backhand index pointing down   * [OPD hubpage](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=160c17f91d&e=d19e9fd41c) * [OPD Briefing: FAQs](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=12c1bc2516&e=d19e9fd41c) * [OPD webinar: on-demand recording](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=2da19611dc&e=d19e9fd41c) * [OPD webinar: slide pack](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=4e682c506a&e=d19e9fd41c) * [OPD Funding and Reimbursement short video](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=27af9e1c8f&e=d19e9fd41c) | | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **National Patient Safety Alert: Discontinuation of Promixin®**  Promixin® (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025 due to the cessation of compatible I-neb devices. Stocks are anticipated to be exhausted by this date.  [Read the advice for primary care providers](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=136635a94e&e=d19e9fd41c) | | |  |  |  | | --- | --- | | |  | | --- | |  | |  |  |  | | --- | --- | | |  | | --- | | [Community Pharmacy England banner](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=c166019b0c&e=d19e9fd41c) | |  |  |  | | --- | --- | | |  | | --- | |  | | | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [Twitter](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=193b507449&e=d19e9fd41c) | | | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [Facebook](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=84bacd2b36&e=d19e9fd41c) | | | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [LinkedIn](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=421f46dbd1&e=d19e9fd41c) | | | | |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | [Website](https://cpe.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=7febc690d3&e=d19e9fd41c) | | | | | | | |  |  |  |  | | --- | --- | --- | | |  |  | | --- | --- | | |  | | --- | | **Community Pharmacy England** Address: 14 Hosier Lane, London EC1A 9LQ Tel: 0203 1220 810 | Email: [comms.team@cpe.org.uk](mailto:comms.team@cpe.org.uk)  *Copyright © 2025 Community Pharmacy England, All rights reserved.*  You are receiving this email because you are subscribed to our newsletters. Please note Community Pharmacy England is the operating name of the Pharmaceutical Services Negotiating Committee (PSNC). | | | | |